Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

Related Posts

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, Gallo G, Okragly A, Wolf E, Xu C, Moser BA, Rueda MJ, Elmaraghy[...]

The liver regulates ectopic calcification in Abcc6-deficient models of Pseudoxanthoma Elasticum

Wang Y, Sun B, Ma F, Tao B, Gu Y, Zhou Z, Kim J, Zhang L, Liu Z, Ten Hoeve J, Stiles L, Fernandez-Del-Rio L,[...]

GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study

Ma EJ, Roberts AM, Jeong CY, Chou P, Katz A, Nong Y, Johnsen N, Yan M, Ochoa MT, Armstrong AW. GLP-1RAs and cardiovascular risk reduction[...]